Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabinoids, including compounds like cannabidiol (CBD) and tetrahydrocannabinol (THC), have been investigated for their potential role in supporting or treating depression. The scientific evidence supporting their use for this indication is limited and mixed. Preclinical studies suggest that cannabinoids may impact neurotransmitter systems involved in mood regulation, such as serotonin and endocannabinoid signaling. Some small-scale clinical studies and surveys have reported improvements in depressive symptoms among individuals using cannabinoids, especially CBD, but these findings are inconsistent and often confounded by other variables (e.g., concurrent anxiety, substance use).

Systematic reviews and meta-analyses generally conclude that there is insufficient high-quality evidence to recommend cannabinoids as a treatment for depression. The American Psychiatric Association and other major medical organizations do not endorse cannabinoids for this purpose. Furthermore, cannabis use, particularly with high-THC products, has been associated with an increased risk of developing or worsening depression in some populations. Adverse effects, such as cognitive impairment and substance use disorder, also warrant caution.

In summary, while there is scientific interest and some preliminary data, the current body of evidence does not robustly support the use of cannabinoids for depression. More rigorous randomized controlled trials are needed to clarify their safety and efficacy.

More about Cannabinoids
More about Depression

Other ingredients used for Depression

Other health conditions supported by Cannabinoids

Products containing Cannabinoids